Physician profile
Hope Cromer
NPI 1053493874
$4,023.44
in general payments reported to CMS, 2019-2025
24 companies · $13.46 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $526 · 2021: $631 · 2022: $992 · 2023: $429 · 2024: $159 · 2025: $13.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $789.88 | 2019-2022 | |
| Lundbeck LLC | $689.14 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $383.72 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $286.35 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.97 | 2020-2023 | |
| Axsome Therapeutics, INC. | $205.40 | 2022-2024 | Auvelity |
| Abbvie INC. | $199.50 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $175.80 | 2019-2025 | Rexulti |
| Allergan, INC. | $142.63 | 2019-2020 | |
| Corium, LLC | $127.91 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $119.29 | 2019 | |
| Neurocrine Biosciences, INC. | $93.14 | 2019-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $88.48 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $87.79 | 2022-2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $74.69 | 2022-2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $60.26 | 2019-2023 | Dyanavel Xr |
| Bausch Health US, LLC | $60.06 | 2019-2024 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $47.68 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $44.76 | 2019 | |
| Alkermes, INC. | $37.97 | 2022 | |
| Neuronetics, INC. | $25.33 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.58 | 2020 | |
| Shire North American Group INC | $16.74 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Cromer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.